Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study
Authors' conclusion
In people with untreated early RA followed up for up to 48 weeks, obesity was associated with a lower likelihood of good treatment response, irrespective of the type of randomised treatment received.
Study context
- Population
- Participants with untreated early rheumatoid arthritis (RA) in the NORD-STAR trial, randomised 1:1:1:1 to active conventional treatment, certolizumab-pegol, abatacept or tocilizumab161 (20%) with obesity
- Participants
- 793 participants
- Comparison
- Obesity vs lower body mass index (BMI)
- Obesityn = 161
- Primary endpoint
- Response to treatment: Clinical Disease Activity Index (CDAI) remission, Simple Disease Activity Index (SDAI) remission and DAS28-CRP <2.6, stratified by BMI
- Follow-up
- Up to 48 weeks
Methodological detailssurvival analyses, stratified by BMI
- Survival analyses
- Stratified by BMI
Primary result
As reported in the abstract
Response to treatment (CDAI remission, SDAI remission, DAS28-CRP <2.6), obesity vs lower BMI; survival analyses
Each group vs lower BMIEstimate (95% CI)
Obesity
HR for achieving CDAI remission 0.84(0.67–1.05)
Obesity
HR for achieving SDAI remission 0.77(0.62–0.97)
Obesity
HR for achieving DAS28-CRP <2.6 0.78(0.64–0.95)
Further findings
Disease activity during follow-up
- Higher disease activity with baseline obesity vs lower BMI, despite similar baseline disease activity
Original publication
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study. RMD Open. Published 4 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →